Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.51 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29509939 | 1.00 | CNR2 (0.65) | CNR2CYP1A2CYP2C9LRRK2SIRT5 | |
| SCHEMBL13069669 | 0.89 | CNR2 (0.60) | CNR2CYP1A2CYP2C9LRRK2SIRT5 | |
| SCHEMBL3377550 | 0.85 | CNR2 (0.65) | CNR2CYP1A2CYP2C9LRRK2 | |
| SCHEMBL29510127 | 0.85 | CNR2 (0.65) | CNR2CYP1A2CYP2C9LRRK2 | |
| SCHEMBL3380963 | 0.85 | CNR2 (0.65) | CNR2CYP1A2CYP2C9LRRK2 | |
| SCHEMBL3378797 | 0.83 | CNR2 (0.65) | CNR2CYP1A2CYP2C9 | |
| SCHEMBL3380525 | 0.82 | CNR2 (0.56) | CNR2CYP1A2CYP2C9LRRK2 | |
| SCHEMBL3377682 | 0.82 | CNR2 (0.65) | CNR2CYP1A2CYP2C9LRRK2 | |
| SCHEMBL3378616 | 0.81 | CNR2 (0.62) | CNR2CYP1A2CYP2C9 | |
| SCHEMBL13503361 | 0.81 | CNR2 (0.76) | CNR2CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1878725-B1 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LTD (GB) | 2010-11-24 | — | — | EP | claimed |
| US-20250268861-A1 | N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS | SPOKE SCIENCES, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12303487-B2 | N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions | SPOKE SCIENCES, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250152509-A1 | PARTICLES, AQUEOUS DISPERSIONS, AND LIQUID COMPOSITIONS HAVING HIGH LIPOPHILIC COMPONENT CONCENTRATIONS AND HIGH LIPOPHILIC COMPONENT TO SURFACTANT RATIOS | SPOKE SCIENCES, INC. (US) | 2025-05-15 | — | — | US | disclosed |
| US-20240261303-A1 | PARTICLES, AQUEOUS DISPERSIONS, AND COMPOSITIONS HAVING HIGH LIPOPHILIC COMPONENT CONCENTRATIONS AND HIGH LIPOPHILIC COMPONENT TO SURFACTANT RATIOS | SPOKE SCIENCES, INC. | 2024-08-08 | — | — | US | disclosed |
| US-20240009208-A1 | STABILIZATION OF CANNABINOIDS WITHIN SOLID DOSAGE FORMS | RECEPTOR HOLDINGS, INC. (US) | 2024-01-11 | — | — | US | disclosed |
| WO-2023201303-A2 | SYSTEMS AND METHODS TO AUTOMATICALLY ADMINISTER A PSYCHOACTIVE SUBSTANCE TO AN AIRWAY OF A USER BASED ON A DETECTED EVENT OR CONDITION | Green Sky Creations, LLC (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20230293479-A1 | MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR HOLDINGS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023102134-A2 | PARTICLES, AQUEOUS DISPERSIONS, AND LIQUID COMPOSITIONS HAVING HIGH LIPOPHILIC COMPONENT CONCENTRATIONS AND HIGH LIPOPHILIC COMPONENT TO SURFACTANT RATIOS | SPOKE SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-11670410-B1 | Systems and methods to automatically administer a psychoactive substance to an airway of a user based on a detected event or condition | Green Sky Creations LLC (US) | 2023-06-06 | — | — | US | disclosed |
| US-7635701-B2 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2009-12-22 | — | — | US | disclosed |
| US-7635701-B2 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2009-12-22 | — | — | US | disclosed |
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| EP-1878725-A2 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2008-01-16 | — | — | EP | disclosed |
| EP-1878725-A2 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20060293354-A1 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2006-12-28 | — | — | US | disclosed |
| EP-1732561-A1 | COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005074939-A1 | COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2005-08-18 | — | — | WO | disclosed |
| EP-1539712-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS CB2 MODULATORS | GLAXO GROUP LIMITED (GB) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004018433-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS CB2 MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293479-A1 | MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | GPR18, SLC1A5, CNR2 | CNR2 3/4885CYP1A2 605/4885CYP2C9 340/4885 |
| US-20250152509-A1 | PARTICLES, AQUEOUS DISPERSIONS, AND LIQUID COMPOSITIONS HAVING HIGH LIPOPHILIC COMPONENT CONCENTRATIONS AND HIGH LIPOPHILIC COMPONENT TO SURFACTANT RATIOS | NAPEPLD, CNR1, CNR2 | CNR2 3/4885CYP1A2 1154/4885CYP2C9 666/4885 |
| US-20250268861-A1 | N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS | FAAH, CNR2, FABP2 | CNR2 2/4885CYP1A2 593/4885CYP2C9 132/4885 |
| US-12303487-B2 | N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions | FAAH, CNR2, FABP2 | CNR2 2/4885CYP1A2 593/4885CYP2C9 132/4885 |
| US-20240009208-A1 | STABILIZATION OF CANNABINOIDS WITHIN SOLID DOSAGE FORMS | DGKZ, DSP, DMPK | CNR2 6/4885CYP1A2 3370/4885CYP2C9 3066/4885 |
| US-20060293354-A1 | Pyrimidine derivatives and their use as CB2 modulators | CNR2, CNR1, P2RX3 | CNR2 1/4885CYP1A2 1273/4885CYP2C9 1187/4885 |
| US-20240261303-A1 | PARTICLES, AQUEOUS DISPERSIONS, AND COMPOSITIONS HAVING HIGH LIPOPHILIC COMPONENT CONCENTRATIONS AND HIGH LIPOPHILIC COMPONENT TO SURFACTANT RATIOS | LIPA, PLIN3, LPL | CNR2 1444/4885CYP1A2 1956/4885CYP2C9 1527/4885 |
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | CNR2, CNR1, PDE4A | CNR2 1/4885CYP1A2 1331/4885CYP2C9 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.